Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial

By HEOR Staff Writer

February 13, 2026

Breakthroughs in Bladder Cancer Treatments at ASCO GU Merck unveiled promising bladder cancer treatments at the 2026 ASCO Genitourinary (GU) Cancers Symposium, showcasing data from its portfolio including KEYTRUDA® (pembrolizuma...
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision

By João L. Carapinha

Exposing Prescription Drug Pricing Flaws Prescription drug pricing in the US is riddled with inefficiencies, as revealed in this JAMA interview published online on Febru...
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões

By João L. Carapinha

February 12, 2026

Robotic Surgery Portugal Achieves Historic First at ULS Viseu Dão-Lafões Robotic surgery Portugal has reached a new milestone with the successful first procedure at the Local Health Unit (ULS) Viseu Dão-Lafões...
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

By João L. Carapinha

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform

By João L. Carapinha

Infarmed 2026 Priorities Take Shape in Leadership Summit Infarmed 2026 priorities crystallized during the Executive Board's February 11, 2026, session with unit directors, led by President Rui Santos Ivo, Vice-President Raque...
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...
View All News
Search By Category

Syenza's Top Picks

CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals

2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solutions

WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults

Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft Annual Work Programme 2026

Preparing for the EU Health Technology Assessment: Key Insights from the Upcoming 2026 Webinar

EU Launches Joint Scientific Consultations to Enhance Health Technology Assessment

Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chronic Disease Medications by 2027

Latest

Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial

By HEOR Staff Writer

February 13, 2026

Breakthroughs in Bladder Cancer Treatments at ASCO GU Merck unveiled promising bladder cancer treatments at the 2026 ASCO Genitourinary (GU) Cancers Symposium, showcasing data from its portfolio including KEYTRUDA® (pembrolizuma...

Latest

Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision

By João L. Carapinha

Exposing Prescription Drug Pricing Flaws Prescription drug pricing in the US is riddled with inefficiencies, as revealed in this JAMA interview published online on Febru...

Latest

Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões

By João L. Carapinha

February 12, 2026

Robotic Surgery Portugal Achieves Historic First at ULS Viseu Dão-Lafões Robotic surgery Portugal has reached a new milestone with the successful first procedure at the Local Health Unit (ULS) Viseu Dão-Lafões...

Latest

Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

By João L. Carapinha

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...

Global Updates

Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision

By João L. Carapinha

February 13, 2026

Exposing Prescription Drug Pricing Flaws Prescription drug pricing in the US is riddled with inefficiencies, as revealed in this JAMA interview published online on Febru...

Global Updates

Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM

By João L. Carapinha

February 10, 2026

ConfiDx Ushers in Uncertainty-Aware Diagnostics Uncertainty-aware diagnostics are transforming clinical decision-making through ConfiDx, a large language model (LLM) trained to recognize diagnostic uncertainty in cases with limited cl...

Global Updates

National HealthTech Access: Transforming NHS Adoption and Equity

By João L. Carapinha

February 9, 2026

HealthTech NHS Access Revolutionized by National Programme HealthTech NHS Access is set to transform through the National HealthTech Access Programme (NHAP), announced by

Global Updates

Launch of TrumpRx Drug Pricing: Savings on Essential Medications

By João L. Carapinha

February 6, 2026

TrumpRx Drug Pricing Launches with Massive Discounts President Donald J. Trump announced the launch of TrumpRx.gov on February 5, 2026, as a cornerstone of TrumpRx drug pricing reforms, enabling American patients to access signif...

Europe

View All
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões

By João L. Carapinha

February 12, 2026

Robotic Surgery Portugal Achieves Historic First at ULS Viseu Dão-Lafões Robotic surgery Portugal has reached a new milestone with the successful first procedure at the Local Health Unit (ULS) Viseu Dão-Lafões...
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform

By João L. Carapinha

Infarmed 2026 Priorities Take Shape in Leadership Summit Infarmed 2026 priorities crystallized during the Executive Board's February 11, 2026, session with unit directors, led by President Rui Santos Ivo, Vice-President Raque...
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes

By HEOR Staff Writer

February 10, 2026

Unlocking Early-Stage Cancer Treatment Gains Early-stage cancer treatment offers significant clinical, humanistic, and economic advantages through timely detection and intervention, yet faces barriers like screening disparities, recurren...

North America

View All
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial

By HEOR Staff Writer

February 13, 2026

Breakthroughs in Bladder Cancer Treatments at ASCO GU Merck unveiled promising bladder cancer treatments at the 2026 ASCO Genitourinary (GU) Cancers Symposium, showcasing data from its portfolio including KEYTRUDA® (pembrolizuma...
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision

By João L. Carapinha

Exposing Prescription Drug Pricing Flaws Prescription drug pricing in the US is riddled with inefficiencies, as revealed in this JAMA interview published online on Febru...
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion in FY 2025

By João L. Carapinha

February 11, 2026

AstraZeneca's financial results for FY and Q4 2025 showcased total revenue of $58.7 billion, up 8% at constant exchange rates (CER) from FY 2024, driven by oncology leadershi...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Resistant Cases

By João L. Carapinha

KEYTRUDA Ovarian Cancer Treatments Gain FDA Nod KEYTRUDA ovarian cancer treatments now include FDA-approved regimens of KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each with paclitaxel ±...

Sub-Saharan Africa

View All
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

By João L. Carapinha

February 12, 2026

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...
South Africa Health Reform: Navigating Innovations and Challenges for 2026

By João L. Carapinha

February 10, 2026

South Africa Health Reform: Contrasts in 2026 Public Health Agenda South Africa health reform defines the 2026 public health landscape as a mix of breakthroughs like HIV prevention injections and AI-driven TB diagnos...
Enhancing Patient Safety in Africa’s Healthcare Transformation

By HEOR Staff Writer

February 2, 2026

Prioritizing Patient Safety Africa in 2026 Trends Patient safety Africa stands at the forefront as regulatory bodies drive healthcare self-reliance amid global shifts. A recent article (linked below) outlines five pivotal trends pro...
Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...